特异性抑制Orai1介导的钙信号可消退炎症并清除急性呼吸窘迫综合征模型中的细菌
急性呼吸窘迫综合征(ARDS)死亡率高达35%且缺乏有效疗法。本研究评估首创新药ELD607(Orai1拮抗剂)在细菌性肺炎所致ARDS临床前模型中的疗效。结果显示ELD607特异性抑制钙库操控性钙内流(SOCE),在体内减少中性粒细胞增多、改善生存并降低肺内细菌负荷,其作用依赖于肺泡巨噬细胞。
要点
- ELD607是首创新药Orai1拮抗剂,可特异性抑制SOCE。
- 吸入ELD607在细菌性肺炎小鼠模型中减少中性粒细胞、改善生存并清除细菌。
- ELD607通过免疫调节作用促进巨噬细胞介导的炎症消退和细菌清除。
核心结论
- 特异性抑制Orai1可能成为减少多器官炎症和治疗耐药细菌的新方法。
研究设计与样本
- 在HEK293T细胞和ARDS患者新鲜分离免疫细胞中评估ELD607药理学。
- 采用细菌性肺炎所致小鼠急性肺损伤模型,感染铜绿假单胞菌、金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌或多重耐药铜绿假单胞菌后经鼻给予ELD607。
主要发现
- ELD607特异性抑制HEK293T细胞SOCE,半数抑制浓度为9 nM。
- ELD607在ARDS气道分泌物中稳定,并抑制ARDS免疫细胞SOCE。
- 吸入ELD607显著减少中性粒细胞增多并改善生存。
- ELD607显著减少肺内细菌,包括耐甲氧西林金黄色葡萄球菌。
- 用吸入氯膦酸盐清除肺泡巨噬细胞后,ELD607不再能消退炎症或清除细菌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Acute respiratory distress syndrome (ARDS) has an unacceptably high mortality rate (35%) and is without effective therapy. Orai1 is a Ca2+ channel involved in store-operated Ca2+ entry (SOCE), a process that exquisitely regulates inflammation. Orai1 is considered a druggable target, but no Orai1-specific inhibitors exist to date. Objectives: To evaluate whether ELD607, a first-in-class Orai1 antagonist, can treat ARDS caused by bacterial pneumonia in preclinical models. Methods: ELD607 pharmacology was evaluated in HEK293T cells and freshly isolated immune cells from patients with ARDS. A murine acute lung injury model caused by bacterial pneumonia was then used: mice were infected with Pseudomonas aeruginosa, Staphylococcus aureus, methicillin-resistant S. aureus, or multidrug-resistant P. aeruginosa and then treated with ELD607 intranasally. Measurements and Main Results: ELD607 specifically inhibited SOCE in HEK293T cells with a half-maximal inhibitory concentration of 9 nM. ELD607 was stable in ARDS airway secretions and inhibited SOCE in ARDS immune cells. In vivo, inhaled ELD607 significantly reduced neutrophilia and improved survival. Surprisingly, Orai1 inhibition by ELD607 caused a significant reduction in lung bacteria, including methicillin-resistant S. aureus. ELD607 worked as an immunomodulator that reduced cytokine levels, reduced neutrophilia, and promoted macrophage-mediated resolution of inflammation and clearance of bacteria. Indeed, when alveolar macrophages were depleted with inhaled clodronate, ELD607 was no longer able to resolve inflammation or clear bacteria. Conclusions: These data indicate that specific Orai1 inhibition by ELD607 may be a novel approach to reduce multiorgan inflammation and treat antibiotic-resistant bacteria.
引用
- Ahmad S, Wrennall JA, Goriounova AS, et al. Specific Inhibition of Orai1-mediated Calcium Signalling Resolves Inflammation and Clears Bacteria in an Acute Respiratory Distress Syndrome Model. Am J Respir Crit Care Med. 2024. PMID: 37972349. doi:10.1164/rccm.202308-1393OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。